SHILPA MEDICARE LTD
GenericsSHILPA MEDICARE LTD is a generic drug manufacturer focused on Oncology.
SHILPA MEDICARE LTD's Key Drugs
SHILPA MEDICARE LTD's core commercial portfolio centers on TENOFOVIR ALAFENAMIDE, spanning Oncology — its most strategically important drugs approved in the last 15 years.
SHILPA MEDICARE LTD's Recent FDA Approvals
New NDA/BLA approvals for SHILPA MEDICARE LTD over the last two years — novel drugs only, excluding generics and label supplements.
SHILPA MEDICARE LTD's Therapeutic Areas
SHILPA MEDICARE LTD's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SHILPA MEDICARE LTD's Top Competitors
SHILPA MEDICARE LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SHILPA MEDICARE LTD Pipeline Snapshot
Active clinical trials for SHILPA MEDICARE LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TENOFOVIR ALAFENAMIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2016-09-29
- Latest
- 2024-12-23
- Applications
- 5